# Newdel Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newdel-biotech

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.newdel.com.cn
- Latest round: Series A (Mar 11, 2024)
- Investors on record: 2

## About

Based in Shenzhen, China, and established in 2021, Shenzhen NewDEL Biotech Co., Ltd., trading as Newdel Biotech, is a biotechnology company that focuses on the R&D and production of new drugs. It is incubated by Guangdong Small Molecule Drug Innovation Center. The company began construction of its DEL 3.0 technology platform in August 2021 and initiated preclinical studies for its original new drug, ND-003, in April 2022. 
Newdel Biotech engages in the R&D of small molecule drugs, focusing on antitumor drugs. The company also provides immune checkpoint inhibitors and anti-infective and metabolic diseases. Those candidate drugs are acquired by DNA Encoded Library (DEL) technology, which is a high throughput live-cell screening technology and can screen membrane proteins that are difficult to purify. It also built a 0-1 drug discovery technology platform (DEL+X) and has a compound library of more than 100 billion real molecules. 
The company generates revenue by developing small molecule innovative drugs.
The company will use the series A+ funding to deepen the research and development and upgrade of Newdel Biotech's "DEL+AI" integrated technology platform, accelerate the layout and clinical development of innovative drug pipelines, and further improve the efficiency and success rate of early drug discovery.

## Funding rounds

- Series A, Mar 11, 2024 — Hecheng Capital
- Angel, Jul 17, 2021 — Cowin Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel
- Hecheng Capital (https://capitalatlas.ai/funds/hecheng-capital) — Series A